問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Rheumatology

Division of Cardiovascular Diseases

更新時間：2023-09-19

廖顯宗Liao, Hsien-Tzung
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

廖顯宗

List

16Cases

2024-11-12 - 2030-12-19

Phase III

Active
A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjogren’s Disease (SjD)

  • Condition/Disease

    Moderate to Severe Sjogren’s Disease (SjD)

  • Test Drug

    injective

Participate Sites
7Sites

Recruiting7Sites

2024-12-20 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-08-30 - 2024-12-17

Phase III

Completed
Prospective, Multi-center, Double-blind, Randomized, Active-controlled, Triple-dummy, Parallel-group, Group-sequential, Adaptive Phase 3 Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed Dose Combination in Subjects With Pulmonary Arterial Hypertension (PAH), Followed by an Open-label Treatment Period With Macitentan and Tadalafil Fixed Dose Combination Therapy

  • Condition/Disease

    Pulmonary Arterial Hypertension (PAH)

  • Test Drug

    M/T FDC, Macitentan 10 mg+Tadalafil 40 mg

Participate Sites
6Sites

Recruiting6Sites

2025-01-03 - 2029-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2016-03-01 - 2023-10-31

Phase III

Active
A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

  • Condition/Disease

    Moderately to Severely Active Rheumatoid Arthritis

  • Test Drug

    ABT-494

Participate Sites
10Sites

Terminated8Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2017-08-15 - 2023-11-30

Phase III

Completed
A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    ABT-494

Participate Sites
7Sites

Terminated6Sites

賴建志
Taipei Veterans General Hospital

Division of Rheumatology

郭昶甫
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2024-10-01 - 2027-12-31

Phase II

Active
A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  • Condition/Disease

    SYSTEMIC LUPUS ERYTHEMATOSUS

  • Test Drug

    injection

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2022-12-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-01-01 - 2030-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-08-01 - 2028-02-29

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB